{
  "task_type": "task2_intervention_profiling",
  "success": true,
  "data": {
    "profiled_interventions": [
      {
        "group_id": "NCT02119676_000",
        "original_group_id": "OG000",
        "group_title": "Substudy 1: Ruxolitinib + Regorafenib",
        "original_description": "Ruxolitinib 15 mg BID continuous with regorafenib 160 mg QD for the first 21 days of each 28-day cycle.",
        "interventions": [
          {
            "name": "Ruxolitinib",
            "original_text": "Ruxolitinib 15 mg BID continuous",
            "type": "drug",
            "dosage_form": "tablet",
            "administration_route": "oral",
            "dosage": "15 mg",
            "frequency": "every 12 hours",
            "Treatment duration": "NA",
            "id": "01"
          },
          {
            "name": "Regorafenib",
            "original_text": "regorafenib 160 mg QD for the first 21 days of each 28-day cycle",
            "type": "drug",
            "dosage_form": "tablet",
            "administration_route": "oral",
            "dosage": "160 mg",
            "frequency": "once a day",
            "Treatment duration": "21 days",
            "id": "02"
          }
        ],
        "administration_sequence": "no order"
      },
      {
        "group_id": "NCT02119676_001",
        "original_group_id": "OG001",
        "group_title": "Substudy 1: Placebo + Regorafenib",
        "original_description": "Placebo BID continuous with regorafenib 160 mg QD for the first 21 days of each 28-day cycle.",
        "interventions": [
          {
            "name": "placebo",
            "original_text": "Placebo BID continuous",
            "type": "drug",
            "dosage_form": "tablet (placebo for regorafenib)",
            "administration_route": "oral",
            "dosage": "NA",
            "frequency": "every 12 hours",
            "Treatment duration": "NA",
            "id": "01"
          },
          {
            "name": "Regorafenib",
            "original_text": "regorafenib 160 mg QD",
            "type": "drug",
            "dosage_form": "tablet",
            "administration_route": "oral",
            "dosage": "160 mg",
            "frequency": "once a day",
            "Treatment duration": "21 days",
            "id": "02"
          }
        ],
        "administration_sequence": "no order"
      },
      {
        "group_id": "NCT02119676_002",
        "original_group_id": "OG002",
        "group_title": "Substudy 2: Ruxolitinib + Regorafenib",
        "original_description": "Ruxolitinib 15 mg BID continuous with regorafenib 160 mg QD for the first 21 days of each 28-day cycle.",
        "interventions": [
          {
            "name": "Ruxolitinib",
            "original_text": "Ruxolitinib 15 mg BID continuous",
            "type": "drug",
            "dosage_form": "NA",
            "administration_route": "NA",
            "dosage": "15 mg",
            "frequency": "every 12 hours",
            "Treatment duration": "NA",
            "id": "01"
          },
          {
            "name": "Regorafenib",
            "original_text": "regorafenib 160 mg QD for the first 21 days of each 28-day cycle",
            "type": "drug",
            "dosage_form": "NA",
            "administration_route": "NA",
            "dosage": "160 mg",
            "frequency": "once a day",
            "Treatment duration": "21 days",
            "id": "02"
          }
        ],
        "administration_sequence": "no order"
      },
      {
        "group_id": "NCT02119676_003",
        "original_group_id": "OG003",
        "group_title": "Substudy 2: Placebo + Regorafenib",
        "original_description": "Placebo BID continuous with regorafenib 160 mg QD for the first 21 days of each 28-day cycle.",
        "interventions": [
          {
            "name": "placebo",
            "original_text": "Placebo BID continuous",
            "type": "drug",
            "dosage_form": "tablet (placebo for regorafenib)",
            "administration_route": "oral",
            "dosage": "NA",
            "frequency": "every 12 hours",
            "Treatment duration": "NA",
            "id": "01"
          },
          {
            "name": "Regorafenib",
            "original_text": "regorafenib 160 mg QD for the first 21 days of each 28-day cycle",
            "type": "drug",
            "dosage_form": "tablet",
            "administration_route": "oral",
            "dosage": "160 mg",
            "frequency": "once a day",
            "Treatment duration": "21 days",
            "id": "02"
          }
        ],
        "administration_sequence": "no order"
      }
    ],
    "co_treat_relations": [
      {
        "head": "Ruxolitinib",
        "relation": "co_treat",
        "tail": "Regorafenib",
        "head_type": "Drug",
        "tail_type": "Drug",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "15 mg",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_000_01"
        },
        "tail_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_000_02"
        },
        "relation_attributes": {
          "group_id": "NCT02119676_000",
          "group_title": "Substudy 1: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "placebo",
        "relation": "co_treat",
        "tail": "Regorafenib",
        "head_type": "Drug",
        "tail_type": "Drug",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet (placebo for regorafenib)",
          "administration_route": "oral",
          "dosage": "NA",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_001_01"
        },
        "tail_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_001_02"
        },
        "relation_attributes": {
          "group_id": "NCT02119676_001",
          "group_title": "Substudy 1: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Ruxolitinib",
        "relation": "co_treat",
        "tail": "Regorafenib",
        "head_type": "Drug",
        "tail_type": "Drug",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "NA",
          "administration_route": "NA",
          "dosage": "15 mg",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_002_01"
        },
        "tail_attributes": {
          "type": "drug",
          "dosage_form": "NA",
          "administration_route": "NA",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_002_02"
        },
        "relation_attributes": {
          "group_id": "NCT02119676_002",
          "group_title": "Substudy 2: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "placebo",
        "relation": "co_treat",
        "tail": "Regorafenib",
        "head_type": "Drug",
        "tail_type": "Drug",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet (placebo for regorafenib)",
          "administration_route": "oral",
          "dosage": "NA",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_003_01"
        },
        "tail_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_003_02"
        },
        "relation_attributes": {
          "group_id": "NCT02119676_003",
          "group_title": "Substudy 2: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      }
    ],
    "composite_relations": [
      {
        "head": "Ruxolitinib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_000",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "15 mg",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_000_01"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_000",
          "group_title": "Substudy 1: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Regorafenib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_000",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_000_02"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_000",
          "group_title": "Substudy 1: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "placebo",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_001",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet (placebo for regorafenib)",
          "administration_route": "oral",
          "dosage": "NA",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_001_01"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_001",
          "group_title": "Substudy 1: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Regorafenib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_001",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_001_02"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_001",
          "group_title": "Substudy 1: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Ruxolitinib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_002",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "NA",
          "administration_route": "NA",
          "dosage": "15 mg",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_002_01"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_002",
          "group_title": "Substudy 2: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Regorafenib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_002",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "NA",
          "administration_route": "NA",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_002_02"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_002",
          "group_title": "Substudy 2: Ruxolitinib + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "placebo",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_003",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet (placebo for regorafenib)",
          "administration_route": "oral",
          "dosage": "NA",
          "frequency": "every 12 hours",
          "Treatment duration": "NA",
          "id": "NCT02119676_003_01"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_003",
          "group_title": "Substudy 2: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      },
      {
        "head": "Regorafenib",
        "relation": "belongs_to_group",
        "tail": "NCT02119676_003",
        "head_type": "Drug",
        "tail_type": "Group",
        "head_attributes": {
          "type": "drug",
          "dosage_form": "tablet",
          "administration_route": "oral",
          "dosage": "160 mg",
          "frequency": "once a day",
          "Treatment duration": "21 days",
          "id": "NCT02119676_003_02"
        },
        "tail_attributes": {
          "group_id": "NCT02119676_003",
          "group_title": "Substudy 2: Placebo + Regorafenib",
          "administration_sequence": "no order"
        }
      }
    ],
    "total_groups": 4,
    "processed_groups": 4,
    "data_source": "ResultsSection.outcomeMeasuresModule",
    "errors": []
  },
  "errors": [],
  "metadata": {}
}